Back

ScientiaCME

  • Castration
  • Fatigue
  • Prostatic Neoplasms

Aiming higher: upping our game in metastatic castration resistant prostate cancer management

In this online, self-learning activity: Prostate cancer (PC) is the most common form of malignancy among men in the U.S. with close to 314,000 new cases and over 35,000 deaths from PC annually. Over the past few decades, the death rates associated with PC have declined, likely due to changes in screening practices and improved treatment options. However, the incidence of PC overall has increased in recent years, and the incidence of mPC at the time of diagnosis is on the rise, accounting for about 8% of those diagnosed. And while patients with local or regional disease have 5-year survival rates close to 100%, that number decreases to 37% for patients with metastatic disease (mPC). Mortality aside, as mPC advances, patients often experience increasing symptom burden, such as persistent fatigue and bone pain, both of which can severely impact their overall quality of life (QoL).

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1 credit

MOC types

ABIM — Medical KnowledgeUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Commercial Support
  • Released
    Nov 25, 2025
  • Last day to claim credit
    Nov 26, 2026 7 weeks left